



US009206123B2

(12) **United States Patent**
Sinha et al.

(10) **Patent No.:** US 9,206,123 B2
(45) **Date of Patent:** Dec. 8, 2015

(54) **PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN**(71) Applicant: **ActiveSite Pharmaceuticals, Inc.**, San Francisco, CA (US)(72) Inventors: **Sukanto Sinha**, San Francisco, CA (US); **Tamie Jo Chilcote**, San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/075,961**(22) Filed: **Nov. 8, 2013**(65) **Prior Publication Data**

US 2014/0128436 A1 May 8, 2014

Related U.S. Application Data

(63) Continuation of application No. 12/972,368, filed on Dec. 17, 2010, now Pat. No. 8,609,866.

(60) Provisional application No. 61/345,045, filed on May 14, 2010, provisional application No. 61/284,478, filed on Dec. 18, 2009.

(51) **Int. Cl.**

C07D 207/35 (2006.01)
C07D 207/34 (2006.01)
G01C 21/36 (2006.01)
C07D 231/14 (2006.01)
C07D 401/04 (2006.01)
C07D 405/04 (2006.01)
C07D 417/04 (2006.01)

(52) **U.S. Cl.**

CPC **C07D 207/34** (2013.01); **C07D 231/14** (2013.01); **C07D 401/04** (2013.01); **C07D 405/04** (2013.01); **C07D 417/04** (2013.01); **G01C 21/3626** (2013.01); **G01C 21/3658** (2013.01)

(58) **Field of Classification Search**

CPC C07D 207/335
USPC 548/542, 561; 514/423
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 5,998,424 A 12/1999 Galemmo, Jr. et al.
6,337,344 B1 1/2002 Defossa et al.
7,144,902 B1 12/2006 Baucke et al.
7,453,002 B2 11/2008 Hangeland et al.
7,625,944 B2 12/2009 Sinha et al.
7,977,380 B2 7/2011 Sinha et al.

FOREIGN PATENT DOCUMENTS

JP	2002-207968 A	3/2002
WO	99/28297 A1	6/1999
WO	00/61609 A2	10/2000
WO	02/14270 A1	2/2002
WO	2006/027135 A1	3/2006
WO	2001-527066 A	12/2007
WO	2008/016883 A2	2/2008
WO	2009/097141 A1	8/2009
WO	2011/075684 A1	6/2011

OTHER PUBLICATIONS

Dorwald, Weinheim F. Zaragoza, *Side Reactions in Organic Synthesis*, (2005) Wiley: VCH Weinheim Preface, pp. 1-15 and Chapter 8, pp. 279-308.

Extended European Search Report mailed Jun. 4, 2013 EP Application No. 10838317, 8 pages.

Govers-Riemslag et al., "The plasma kallikrein-kinin system and risk of cardiovascular disease in men," *Journal of Thromosis and Haemostasis*, 2007, 5, 1896-903.

International Search Report and Written Opinion, date May 23, 2011, PCT application No. PCT/US10/61122, 11 pages.

Koshio et al., "Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives," *Bioorganic and Medicinal Chemistry*, 2004, vol. 12, pp. 5415-5426.

Phipps, J.A. et al., "The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney," *Kidney International*, 2008, 73, 1114-9.

Phipps, JoAnna A. et al., "Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability," *Hypertension*, 2009, vol. 53, pp. 175-181.


Schmaier, Alvin H., "The plasma kallikrein-kinin system counterbalances the renin-angiotensin system," *Clin. Invest.*, 2002, 109, 1007-9.

Primary Examiner — Patricia L Morris

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP; William B. Kezer

(57) **ABSTRACT**

The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:



11 Claims, 6 Drawing Sheets